Eisai Co., Ltd. and Biogen Inc. have announced encouraging findings from their Lecanemab in Early Alzheimer's Disease (LEADER) Study, revealing that 82.5% of participants either remained stable or showed improvement over an average of 17 months of therapy. The results, presented at the Alzheimer's Association International Conference 2026, indicate that LEQEMBI treatment may help slow cognitive decline and maintain daily […]